ATE481105T1 - Wässrige zusammensetzungen mit metronidazol - Google Patents

Wässrige zusammensetzungen mit metronidazol

Info

Publication number
ATE481105T1
ATE481105T1 AT02778822T AT02778822T ATE481105T1 AT E481105 T1 ATE481105 T1 AT E481105T1 AT 02778822 T AT02778822 T AT 02778822T AT 02778822 T AT02778822 T AT 02778822T AT E481105 T1 ATE481105 T1 AT E481105T1
Authority
AT
Austria
Prior art keywords
compositions containing
aqueous compositions
containing metronidazole
metronidazole
aqueous
Prior art date
Application number
AT02778822T
Other languages
German (de)
English (en)
Inventor
Yunik Chang
Gordon Dow
Original Assignee
Dow Pharmaceutical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21872727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE481105(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Pharmaceutical Sciences filed Critical Dow Pharmaceutical Sciences
Application granted granted Critical
Publication of ATE481105T1 publication Critical patent/ATE481105T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
    • C08J2301/02—Cellulose; Modified cellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02778822T 2001-12-24 2002-11-07 Wässrige zusammensetzungen mit metronidazol ATE481105T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/033,835 US6881726B2 (en) 2001-12-24 2001-12-24 Aqueous compositions containing metronidazole
PCT/US2002/036063 WO2003057135A2 (en) 2001-12-24 2002-11-07 Aqueous compositions containing metronidazole

Publications (1)

Publication Number Publication Date
ATE481105T1 true ATE481105T1 (de) 2010-10-15

Family

ID=21872727

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02778822T ATE481105T1 (de) 2001-12-24 2002-11-07 Wässrige zusammensetzungen mit metronidazol

Country Status (19)

Country Link
US (4) US6881726B2 (enExample)
EP (3) EP1467744B1 (enExample)
JP (1) JP4611632B2 (enExample)
KR (1) KR100718858B1 (enExample)
CN (1) CN100411624C (enExample)
AR (1) AR037755A1 (enExample)
AT (1) ATE481105T1 (enExample)
AU (1) AU2002340458B2 (enExample)
BR (1) BRPI0215331B8 (enExample)
CA (1) CA2470492C (enExample)
CY (1) CY1111095T1 (enExample)
DE (1) DE60237710D1 (enExample)
DK (1) DK1467744T3 (enExample)
ES (1) ES2352656T3 (enExample)
MX (1) MXPA04006210A (enExample)
PT (1) PT1467744E (enExample)
RU (2) RU2284810C2 (enExample)
WO (1) WO2003057135A2 (enExample)
ZA (1) ZA200405059B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
DE10306453A1 (de) * 2003-02-17 2004-08-26 Deutsche Telekom Ag Administrator
US7456207B2 (en) * 2003-09-25 2008-11-25 Teva Pharmaceuticals Usa, Inc. Vaginal pharmaceutical compositions and methods for preparing them
FR2866566A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US9446226B2 (en) * 2005-12-07 2016-09-20 Ramot At Tel-Aviv University Ltd. Drug-delivering composite structures
US20100105638A1 (en) * 2007-03-12 2010-04-29 Kerstin Den-Braven Cosmetic compositions
US20080287514A1 (en) * 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080287513A1 (en) * 2007-05-14 2008-11-20 Jerry Zhang Topical compositions containing metronidazole
US20080312304A1 (en) * 2007-06-13 2008-12-18 Jerry Zhang Topical compositions containing metronidazole
ES2439497T3 (es) * 2007-09-04 2014-01-23 Meiji Seika Pharma Co., Ltd. Preparación de una inyección, de una solución para inyección y de un kit de inyección
AR061947A1 (es) * 2008-01-08 2008-08-10 Oscar Belluscio Daniel Metodo para la obtencion del complejo gonadotrofina corionica humana (gch) / ciclodextrina administrable por via oral, producto obtenido con dicho metodo y uso clinico-terapeutico del complejo gonadotrofina corionica humana (gch) / ciclodextrina
US7893097B2 (en) * 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
EP2303353B1 (en) * 2008-06-12 2018-01-10 Ramot at Tel-Aviv University Ltd. Drug-eluting medical devices
US8729108B2 (en) * 2008-06-17 2014-05-20 Christopher J Dannaker Waterborne topical compositions for the delivery of active ingredients such as azelaic acid
WO2010047831A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
EP2201930A1 (en) 2008-12-23 2010-06-30 Intendis GmbH Hydrogel composition for the treatment of dermatological disorders
AU2010237599A1 (en) * 2009-04-14 2011-12-08 Medortus (Uk) Ltd Gel compositions for administration of pharmaceutically active compounds
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
CN105903028B (zh) * 2010-12-31 2020-10-16 东塘实验室有限公司 含有环糊精的细胞水合组合物
EP2658578A1 (en) * 2010-12-31 2013-11-06 Eastpond Laboratories Limited Cellular hydration compositions containing cyclodextrins
JP5864615B2 (ja) 2011-01-25 2016-02-17 ザ プロクター アンド ギャンブルカンパニー リポソーム及びそれを含むパーソナルケア組成物
CA2840571C (en) * 2011-06-28 2020-03-24 Medicis Pharmaceutical Corporation High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
JP2015044850A (ja) * 2014-11-07 2015-03-12 イーストポンド・ラボラトリーズ・リミテッド シクロデキストリンを含有する細胞水和組成物
US9492374B2 (en) * 2015-03-25 2016-11-15 Jose Rafael Salinas Andrade Composition and method for treatment of ulcers
DK3723739T3 (da) 2017-12-15 2024-06-17 Tarsus Pharmaceuticals Inc Isoxazolin-parasiticidformuleringer og deres anvendelse til behandling af blepharitis
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
CN111840632A (zh) * 2019-04-25 2020-10-30 广东泰宝医疗科技股份有限公司 一种含止血微囊的液体敷料及其制备方法
WO2021246966A1 (en) * 2020-06-02 2021-12-09 National University Of Singapore Compositions, their uses in therapy and methods thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032645A (en) * 1975-06-19 1977-06-28 G. D. Searle & Co. Injectable metronidazole composition
US4267169A (en) * 1978-07-22 1981-05-12 Toko Yakuhin Kogyo Kabushiki Kaisha Novel preparation of clotrimazole
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
EP0335545B2 (en) 1988-03-29 1998-09-23 University Of Florida Pharmaceutical formulations for parenteral use
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
RU2029548C1 (ru) * 1989-07-07 1995-02-27 Центр по химии лекарственных средств Антимикробное или радиосенсибилизирующее средство
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
TW200402B (enExample) 1990-08-13 1993-02-21 Senju Pharma Co
DE69232535D1 (de) * 1991-06-24 2002-05-08 Pacific Biomedical Res Inc In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
US5747341A (en) * 1991-06-24 1998-05-05 Pacific Biomedical Research, Inc. Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
DE69533724T2 (de) * 1994-03-28 2005-10-27 The Trustees Of Columbia University In The City Of New York Zusammensetzung zum inaktivieren von reizstoffen in flüssigkeiten
FR2722098B1 (fr) * 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
EP1007049A1 (en) * 1997-08-27 2000-06-14 Hexal AG New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6017516A (en) * 1997-10-31 2000-01-25 Lekar Pharma Limited Pharmaceutical dental formulation for topical application of metronidazole benzoate and chlorhexidine gluconate
US6183766B1 (en) * 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
CN1116038C (zh) * 2000-11-18 2003-07-30 雷文彬 一种治疗痤疮的外用药液

Also Published As

Publication number Publication date
BRPI0215331B8 (pt) 2021-05-25
DK1467744T3 (da) 2010-12-20
US20080154030A1 (en) 2008-06-26
AR037755A1 (es) 2004-12-01
ZA200405059B (en) 2005-09-28
AU2002340458B2 (en) 2007-01-04
JP4611632B2 (ja) 2011-01-12
CN1649603A (zh) 2005-08-03
CN100411624C (zh) 2008-08-20
CA2470492A1 (en) 2003-07-17
RU2284810C2 (ru) 2006-10-10
US20030119783A1 (en) 2003-06-26
EP1467744A2 (en) 2004-10-20
CA2470492C (en) 2010-02-23
AU2002340458A1 (en) 2003-07-24
DE60237710D1 (de) 2010-10-28
WO2003057135A2 (en) 2003-07-17
KR20040075911A (ko) 2004-08-30
EP2238980A1 (en) 2010-10-13
EP1467744A4 (en) 2006-07-05
JP2005532990A (ja) 2005-11-04
ES2352656T3 (es) 2011-02-22
US20050124578A1 (en) 2005-06-09
PT1467744E (pt) 2010-11-30
US20100048659A1 (en) 2010-02-25
EP2241320A1 (en) 2010-10-20
KR100718858B1 (ko) 2007-05-16
RU2004122696A (ru) 2005-03-20
BRPI0215331B1 (pt) 2015-07-28
US7348317B2 (en) 2008-03-25
RU2413501C2 (ru) 2011-03-10
HK1071514A1 (en) 2005-07-22
CY1111095T1 (el) 2015-06-11
EP1467744B1 (en) 2010-09-15
RU2006116252A (ru) 2007-12-10
MXPA04006210A (es) 2005-05-17
WO2003057135A3 (en) 2003-12-18
BR0215331A (pt) 2005-05-10
US6881726B2 (en) 2005-04-19

Similar Documents

Publication Publication Date Title
ATE481105T1 (de) Wässrige zusammensetzungen mit metronidazol
ATE506950T1 (de) Zusammensetzungen enthaltend metronidazol
DE60219383D1 (de) Wässrige Beschichtungszusammensetzung
UY3281Q (es) Envase
UY3346Q (es) Envase
UY3347Q (es) Envase
DK1358165T3 (da) Imidazolderivater
UY3304Q (es) Envase
ATE450652T1 (de) Wässrige zusammensetzung
DE50214751D1 (de) Dosiervorrichtung
DE60133103D1 (de) Behälter
DE50101075D1 (de) Container
NO20040108L (no) Vandige blandinger omfattende en kjemisk mikrogel assosiert med en vandig polymer
ATA6842001A (de) Tank
ATE405574T1 (de) Aryl-annellierte azapolyzyklische verbindungen
DE60219603D1 (de) Behälter
ITTO20020744A1 (it) Composizione.
FI5314U1 (fi) Kontti
DE60223671D1 (de) Dosierpumpe
ITTO20020745A1 (it) Composizione.
DE50213685D1 (de) Dosiervorrichtung
ITTO20020746A1 (it) Composizione.
UA5107S (uk) Упаковка для кетчупа
FI5160U1 (fi) Kontti
ITMI20011739A0 (it) Contenitore

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1467744

Country of ref document: EP